Video

Dr. Champlin on the Role of EASIX Following Allogeneic Stem Cell Transplant

Richard E. Champlin, MD, a professor of medicine at MD Anderson Cancer Center, discusses the association seen between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent an allogenic stem cell transplantation.

Richard E. Champlin, a professor of medicine at The University of Texas MD Anderson Cancer Center, discusses the association reported between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent allogenic stem cell transplantation (SCT).

Grade ≥2 fluid overload has been determined to be a significant adverse event with nonrelapse mortality in patients with allogenic SCT, and researchers hypothesized that endothelial damage to prior treatments before receiving allogenic SCT can be associated with this type of toxicity. In the study, predictors of ≥2 fluid overload and 6-month overall survival were evaluated, as well as EASIX scores.

Findings showed that an elevated EASIX index can identify a group of patients who are at high risk for treatment-related mortality, Champlin explains. By identifying these patients, physicians can introduce interventions that can reduce fluid and improve capillary gut syndrome. There are agents available that could reduce fluid overload appropriately in this high-risk group, he concludes.

<<< 2019 Transplantation and Cellular Therapy Meetings

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO